Business Wire

BLUEHOLE-NEW-CONSUMPTION

29.3.2022 04:15:10 CEST | Business Wire | Press release

Share
Bluehole Publishes an Industry Comment on the World's First E&L Testing Laboratory in the Vaping Industry

China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on SMOORE‘s establishment of the world’s first E&L testing laboratory in the vaping industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005929/en/

Here below is the full article:

SMOORE, a global leader in offering vaping technology solutions, today announced the establishment of the world’s first extractable and leachable (E&L) testing laboratory in the vaping industry.

Built in the last half of 2021, this laboratory conducts qualitative and quantitative analytical testing and health risk assessment of E&L substances of electronic atomization components, including metals, plastics and other polymers.

As China’s first electronic atomization company to develop a PMTA (Premarket Tobacco Product Applications)-compliant assessment system, including physical tests, chemical tests, non-clinical testing and health risk assessment, SMOORE also set up this E&L testing laboratory based on PMTA safety requirements.

Moreover, SMOORE's E&L testing laboratory is in collaboration with SMITHERS, a world-leading provider of testing, consulting, information, and compliance services. For years, the two companies have worked closely on PMTA compliance.

Currently, most companies in the vaping industry rely on third-party laboratories for E&L testing while SMOORE has set up an in-house laboratory with comprehensive and advanced testing equipment. It follows the analytical methodology of the world’s leading E&L testing laboratories for medical devices.

As SMOORE’s flagship atomization tech brand, FEELM is able to make full use of SMOORE’s world-class testing and risk assessment system, including this E&L testing laboratory. Since 2021, FEELM has leveraged the laboratory for the safety assessment of its electronic atomization components, to guarantee the quality and reliability of FEELM's new products.

In October 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK has planned to integrate medicinally licensed e-cigarettes into the National Health Service (NHS). Other countries, including Australia, have also prescribed adult smokers e-cigarettes to reduce smoking rates. As global regulators started embracing e-cigarettes, they are setting higher safety requirements for e-cigarettes, and SMOORE takes the lead to improve the material reliability of e-cigarettes to medical grade.

E&L analytical testing is widely used in the field of pharmaceutical research and development. The E&L compounds of the packaging materials of pharmaceutical products must be tested before launch, to ensure the product safety compliance.

SMOORE's E&L testing laboratory can provide safety assessment for not only e-cigarettes but also electronic atomization products in other sectors. With one of its R&D focus on the application of atomization technology in healthcare and pharmaceutical fields, SMOORE could leverage this laboratory for the development of healthcare atomization innovations.

"The safety of electronic atomization products primarily depends on the chemical composition of e-liquid and the vapor generated by e-liquid atomization, as well as the E&L substances of other materials in contact with human bodies", said Dr. Long, Director of Analytical Testing and Safety Assessment of SMOORE Fundamental Research Center. "Our E&L testing laboratory specializes in the latter."

According to Dr. Long, SMOORE Fundamental Research Center plans to establish and complete a database of E&L substances in electronic atomization components, and will adopt the principle of Good Laboratory Practice (GLP) to ensure the quality and integrity of test data related to non-clinical safety studies. Meanwhile, SMOORE Fundamental Research Center is also looking for partnership with more Chinese medical device providers on E&L testing.

Since 2020, SMOORE has established its own safety standards, SMOORE 3.0, in accordance with the risk assessment guidance of U.S. EPA (Environmental Protection Agency). Above the safety requirements of the Tobacco Products Directive (TPD) of the EU and AFNOR of France, SMOORE 3.0 covers all of the PMTA tests, including both material safety and vapor safety.

To read the original article, please visit: https://www.bluehole.com.cn/news/detail/49078

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Special Olympics Airlift Takes Flight Nationwide; Dove 1 Arrives at St. Paul Downtown Airport19.6.2026 17:09:00 CEST | Press release

Approximately 130 Cessna, Beechcraft and Hawker aircraft and volunteer pilots mobilize to transport more than 800 Special Olympics athletes and coaches to the 2026 Special Olympics USA Games The 2026 Special Olympics Airlift officially took flight today as all participating Cessna, Beechcraft and Hawker aircraft, known as Doves, departed from airports across the country. Dove 1 for arrival day, a Cessna Citation Latitude generously operated by Prent Corporation, landed at St. Paul Downtown Airport (STP) carrying Special Olympic athletes and delegation members, signaling the start of Airlift arrivals for the Special Olympics USA Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619085293/en/ Special Olympics Airlift takes flight nationwide; Dove 1 arrives at St. Paul Downtown Airport (Photo credit: Textron Aviation). The arrival signals the start of the world’s largest cumulative peacetime airlift spanning more than 40

Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 16:53:00 CEST | Press release

Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye